London, April 28, 2021 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has signed an exclusive license and distribution agreement with AFT Pharmaceuticals (AFT) for the commercialisation of Combogesic® IV, the US trade name of Maxigesic IV, an intravenous, opioid free post-operative pain relief medicine.
28 April 2021
Corporate, Press Release
The licensing agreement provides Hikma with exclusive rights for the sales, marketing and distribution of Combogesic® IV in the US. Combogesic® IV (paracetamol 1000mg + ibuprofen 300mg solution for infusion) is a patented intravenous formulation developed as a line extension to Maxigesic tablets, for use post-operatively in hospitals when patients cannot take a medicine orally. AFT expects to file Combogesic® IV for approval with the US FDA in the coming months.
“We are pleased to enter into this partnership with AFT for Combogesic® IV, an important alternative for the treatment of post-operative pain,” said Riad Mishlawi, President, Hikma Injectables. “This agreement is another example of how Hikma is continuing to expand its pipeline in growing therapeutic areas like non-opioid pain management treatments, and highlights the importance of partnerships in expanding our ability to offer a broad portfolio of high-quality medicines to US patients, physicians and hospitals.”